Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over study for continued darolutamide treatment
2019-003618-15Phase 3Active
- Sponsor
- Bayer Consumer Health
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darolutamide in cancer, sponsored by Bayer Consumer Health. Primary endpoint: Incidence of treatment-emergent adverse events. Started Apr 2020; status: active.
02
Drugs
darolutamide
03
Conditions
cancer
Beyond the preview
Go deeper on 2019-003618-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003618-15.